Glenmark Pharmaceuticals

Glenmark Pharmaceuticals (₹2,590) is exhibiting strong daily momentum on 2026-11-06, marked by an extreme volume-price anomaly with a 7.98x volume ratio and a +4.4% close gain. The stock is trading near its 20-day and 50-day range highs (+84.1%) and at the upper end of its 252-day range (+89.5%). Daily trend indicators are bullish: price sits above all key moving averages (EMA/SMA 20/50/200) and the Supertrend, supported by an established ADX of 31.32. However, this short-term strength contrasts with a bearish monthly Supertrend despite high monthly ADM conviction (ADX 57.72), suggesting the current rally may be testing longer-term resistance. Immediate upside faces resistance at ₹2,615.67 (+0.99%), while downside support lies at ₹2,578.93 (-0.43%) and ₹2,530.37 (-2.30%). Volatility remains elevated (ATR 3.47%, annualized vol 30.8%). A sustained break above ₹2,615.67 with continued volume would confirm further daily upside, whereas a failure to hold above ₹2,578.93 could signal a pullback toward the ₹2,530 pivot.

Glenmark Pharmaceuticals reported Q2 FY27 results on November 6, 2026, showing a 56.8% year-on-year decline in profit and a nearly 30% drop in revenue to ₹4,247.3 crore. The company clarified that its core North American business grew approximately 31% when excluding deferred out-licensing income, while India formulations expanded by around 14%. US sales of $126.6 million exceeded analyst estimates of $105 million but remained significantly lower than prior-year figures. Despite the earnings contraction, Glenmark maintained its full-year FY27 revenue guidance of Rs 17,000-18,000 crore and Ebitda margin target of 21-22%. Shares fell approximately 4% following the announcement.

Glenmark Pharmaceuticals reported Q2 FY2026-27 results on November 5, 2026, showing consolidated revenue of ₹4,247.3 million and adjusted PAT of ₹4,852 million. While the company highlighted strong like-for-like growth of approximately 20% in revenue and 31% in core North American business (excluding deferred out-licensing income), reported headline profit fell 56.8% year-on-year due to a US$15.28 million settlement with Humana Inc. for antitrust litigation. The stock price rose to ₹2,590.0 on November 6 from ₹2,481.8 previously, despite market headlines noting a 4% intraday fall following initial profit decline reports. Management maintained full-year FY27 guidance of ₹17,000–18,000 crore revenue and 21–22% EBITDA margin.

Glenmark Pharmaceuticals reported consolidated revenue of Rs. 42,473 million for Q2 FY 2026-27, reflecting approximately 20% like-for-like year-over-year growth. Adjusted Profit After Tax (PAT) was Rs. 4,852 million with an EBITDA margin of 20.3%. The half-year results included an exceptional item of Rs. 2,838.75 million, primarily driven by a US$15 million settlement with Humana, Inc., related to U.S. antitrust litigation; the company clarified this settlement does not involve an admission of liability. Regional performance showed strong momentum in North America (~31% core growth) and Emerging Markets (33.2%), while India grew ~14%. Commercially, the company launched RYALTRIS® in Brazil and WINLEVI® in several EU markets, and secured regulatory approvals for Trastuzumab RezeteCan in Australia. Additionally, Ichnos Glenmark Innovation (IGI) will present updated clinical data for ISB 2001 at the ASH Annual Meeting in December 2026.

Glenmark Pharmaceuticals demonstrates a significant acceleration in top-line growth, with TTM sales rising to ₹17,737 crore and YoY sales growth reaching 76% for the Sep 2025 quarter. This expansion is accompanied by robust profitability improvements; TTM net profit surged to ₹1,798 crore, and ROCE improved sharply to 40% as of Mar 2026. However, earnings quality faces scrutiny due to a sharp sequential decline in Q2 FY2026-27, where net profit fell from ₹483 crore to ₹264 crore despite revenue growth. Cash flow dynamics have also shifted, with CFO swinging from negative territory in prior years to ₹3,445 crore in Mar 2026, though cash reserves decreased to ₹1,290 crore by Sep 2026. Working capital efficiency has deteriorated, with debtor days increasing to 107 days.

Glenmark Pharmaceuticals presents a conditional upside case anchored in operational resilience and technical momentum, despite reported headline profit declines. The company’s core North American business grew approximately 31% when excluding deferred out-licensing income, demonstrating underlying commercial strength. Additionally, the India formulation business achieved like-for-like growth of around 14%, providing a stable domestic counterweight to US volatility. Financially, Glenmark maintained its full-year FY27 revenue guidance of ₹17,000–18,000 crore and an EBITDA margin target of 21–22%, signaling management confidence in future performance. Technically, the stock exhibits bullish signals on both daily and weekly timeframes as of November 6, 2026, with the Supertrend indicating upward momentum and significant period returns, including a +43.1% gain over the last year. This constructive interpretation holds provided that US sales execution remains robust and the company meets its stated margin targets.

Glenmark Pharmaceuticals reported a sharp deterioration in Q2 FY27 profitability, with net profit plunging 56.8% year-on-year and revenue declining nearly 30% to ₹4,247.3 crore. This contraction was primarily driven by steep drops in North American earnings, although the company clarified that core US business grew approximately 31% when excluding deferred out-licensing income. Despite these headline declines, management maintained its full-year FY27 revenue guidance of ₹17,000–18,000 crore and EBITDA margin target of 21–22%. The market reacted negatively, with shares falling approximately 4% on November 6, 2026, closing at ₹2,590. While technical indicators show a bullish daily supertrend and strong recent returns (YTD +27.8%, 1-year +43.1%), the monthly trend remains bearish, and the stock has experienced a maximum drawdown of -22.1% over the measured period.